Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals (Nasdaq: RIGL) announced inducement equity awards under its Inducement Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Rhea-AI Summary
Rigel Pharmaceuticals (Nasdaq: RIGL) announced inducement equity awards under its Inducement Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
The company granted 24,775 stock options and 16,555 restricted stock units (RSUs) to 11 non-executive employees. Awards vest over four years with a one-year cliff. Grants were approved by the Compensation Committee and issued as inducements for new hires.
Positive
- None.
Negative
- None.
Details
News Market Reaction – RIGL
In the Jan 9 session, RIGL declined 8.22%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Stock options granted
- 24,775 options
- Inducement awards to new employees under NASDAQ Listing Rule 5635(c)(4)
- RSUs granted
- 16,555 restricted stock units
- Inducement awards to new employees
- Employees receiving awards
- 11 non-executive employees
- Recipients of stock options and RSUs
- Vesting period
- 4 years
- Equity awards vest over four years with a one-year cliff
- Cliff period
- 1 year
- Initial cliff before vesting of inducement grants
- Company founding
- 1996
- Year Rigel Pharmaceuticals was founded
Historical Context
-
Announcement of company presentation at J.P. Morgan Healthcare Conference.
-
Planned company overview at Piper Sandler healthcare conference.
-
Publication of five-year REZLIDHIA Phase 2 efficacy and safety data.
-
Jefferies Global Healthcare Conference presentation announcement.
-
Strong Q3 2025 revenues, profitability, and raised full-year guidance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
inducement plan financial
stock options financial
restricted stock units financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
Contact for Investors & Media
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302656921.html
SOURCE Rigel Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
